We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener's granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented.
No takes yet. Share an insight, caveat, or question.
Oristrell et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: